ESTRO 36 Abstract Book

412 / 1096

S397 ESTRO 36
_______________________________________________________________________________________________
1.02) for low birth weight, 0.6 (0.45-0.80) for prematurity,
0.97 (0.75-1.27) for small for gestational age, 0.82 (0.65-
1.04) for large for gestational age, 0.98 (0.69-1.38) for
foetal distress, 1.21 (0.92-1.59) for any foetal
abnormalities, 1.36 (0.56-3.29) for central nervous system
malformation, 1.39 (0.62-3.09) for chromosomal
abnormalities, and 1.20 (0.77-1.87) for other/unspecified
abnormalities. The risks of Apgar score < 7 in 1 minute and
in 5 minutes were not significant increased with ORs of
0.71 (0.43-1.18) and 0.62 (0.20-1.94).
Conclusion
For female cancer patients who received radiotherapy,
there were no significant increasing their adverse birth
outcomes compared to women without malignancies.
PO-0753 Radiation therapy and outcome in cancer
patients with acute venous thromboembolism.
J.B. Guy1, L. Bertoletti2 , N. Magné1, I. Mahé3, C. Font4,
O. Sanz5, J.M. Martín-Antorán6, F. Pace7, J. Ramón Vela8,
M. Monreal9
1 Lucien Neuwirth Cancer Institute, Radiation Oncology,
St Priest en Jarez, France
2 CHU Saint-Etienne, Vascular and Therapeutic Medicine,
St Priest en Jarez, France
3 Hopital Louis Mourier, Internal Medicine, Colombes,
France
4 Hospital Clínic de Barcelona, Medical Oncology,
Barcelona, Spain
5 Hospital Universitario de Gran Canaria Dr. Negrín,
Internal Medicine, Las Palmas, Spain
6 Hospital Río Carrión, Haemostasis and Thrombosis,
Palencia, Spain
7 Ospedale San Camillo, Medicina d´Urgenza, Rome, Italy
8 Hospital Universitario Miguel Servet, Internal Medicine,
Zaragoza, Spain
9 Hospital Universitari Germans Trias i Pujol, Internal
Medicine, Barcelona, Spain
Purpose or Objective
There is lack of evidence on the influence of radiation
therapy (RT) on outcome in cancer patients with acute
venous thromboembolism (VTE).
Material and Methods
RIETE (Registro Informatizado Enfermedad Trombo
Embólica) is an ongoing, multicenter, observational
registry of consecutive patients with symptomatic,
objectively confirmed, acute VTE. We used the RIETE
database to compare the rate of VTE recurrences and
major bleeding during the course of anticoagulation in
cancer patients with or without RT.
Results
As of May 2015, 9284 patients with active cancer and VTE
were enrolled in RIETE: 4605 with pulmonary embolism
(PE) and 4679 with deep vein thrombosis (DVT). In all,
1202 (13%) were receiving RT. During the course of
anticoagulant therapy (mean: 181 days), 210 patients
presented with PE recurrences (53 fatal), 226 with DVT
recurrences and 443 with major bleeding (60 in the brain,
118 fatal). Patients receiving RT had a higher rate of PE
recurrences (risk ratio [RR]: 1.56; 95%CI: 1.08-2.21) and a
similar rate of DVT recurrences (RR: 0.80; 95%CI: 0.50-
1.22) or major bleeding (RR: 1.18; 95%CI: 0.90-1.55) than
those not receiving RT. Moreover, patients on RT had a
higher rate of cerebral bleeding (RR: 2.05; 95%CI: 1.07-
3.71). Multivariable analysis confirmed that patients
receiving radiotherapy were at an increased risk for
cerebral bleeding (hazard ratio: 2.71; 95%CI: 1.13-6.48).
Conclusion
During the course of anticoagulant therapy, cancer
patients with VTE receiving RT had a higher rate of PE
recurrence and a higher rate of cerebral bleeding than
those not receiving RT.
PO-0754 ISIORT pooled analysis 2016: characteristics
of intraoperative radiotherapy in 11,025 patients
M. Krengli1, F. Calvo2, F. Sedlmayer3, C. Schumacher4, F.
Cazzaniga5, M. Alessandro 6, A. De Paoli 7, E. Russi8, M.
Kruszyna9, R. Corvò10, F. Wenz11, R. Mazzarotto 12, F.
Fusconi13 , A. Ciabattoni14, R. Weytjens15, G. Ivaldi16, A.
Baldissera 17, C. Pisani1, V. Morillo18, M. Osti19, N. Bese20,
G. Catalano21, A. Stefanelli22, C. Iotti23, L. Tomio24
1University of Piemonte Orientale, Radiotherapy,
Novara, Italy
2Gregorio Maranon, Radiotherapy, Madrid, Spain
3Paracelsus Medical University, Radiotherapy, Salzburg,
Austria
4St. Elisabeth Hospital, Radiotherapy, Cologne, Germany
5ASST Papa Giovanni XXIII, Radiotherapy, Bergamo, Italy
6Ospedale USL1, Radiotherapy, Città di Castello, Italy
7CRO, Radiotherapy, Aviano, Italy
8Azienda Ospedaliera S. Croce e Carle, Radiotherapy,
Cuneo, Italy
9Hospital, Radiotherapy, Poznan, Poland
10Ospedale San Martino, Radiotherapy, Genova, Italy
11University Hospital, Radiotherapy, Mannheim, Germany
12University Hospital, Radiotherapy, Verona, Italy
13Hospital, Radiotherapy, Foligno, Italy
14San Filippo Neri Hospital, Radiotherapy, Roma, Italy
15GasthuisZusters Antwerpen -GZA, Radiotherapy,
Wilrijk, Belgium
16Fondazione Maugeri, Radiotherapy, Pavia, Italy
17Bellaria Hospital, Radiotherapy, Bologna, Italy
18Hospital General Universitario de Castellón,
Radiotherapy, Castellon, Spain
19Sant'Andrea Hospital, Radiotherapy, Roma, Italy
20Acibadem Maslak Hospital, Radiotherapy, Istanbul,
Turkey
21Multimedica Hospital, Radiotherapy, Sesto San
Giovanni- Castellanza, Italy
22Sant'Anna Hospital, Radiotherapy, Ferrara, Italy
23Azienda Ospedaliera di Reggio Emilia, Radiotherapy,
Reggio Emilia, Italy
24Santa Chiara Hospital, Radiotherapy, Trento, Italy
Purpose or Objective
Data from centres active in intraoperative radiotherapy
(IORT) were collected within the International Society of
Intraoperative Radiotherapy (ISIORT) program. The
purpose of the present analysis was to analyse and report
the main clinical and technical variables of IORT
performed by the participating centres.
Material and Methods
In 2007, the ISIORT-Europe centres were invited to record
demographic, clinical and technical data relating to their
IORT procedures in a joint online database.
Results
The numbers of centres increased from 3 centres in 2007
to 42 centres and 11,025 IORT procedures have been
recorded until October, 2016. 96% of treatment was
performed with electrons, while 448 treatments were
performed with x-rays. Median age of patients was 56.2
years (range: 5 months – 89 years). Gender was female in
81.2% of cases and male in 18.8%. Treatments were
curative in 10,482 cases (98.2%) and 2,545 (23.8%) cases
were included in study protocols. The most frequent
tumour was breast cancer with 8,425 cases (76.4%)
followed by rectal cancer with 913 cases (8.3%), soft tissue
and bone sarcomas with 348 cases (3.2%), prostate cancer
with 165 cases (1.5%), gastric cancer with 120 cases (1.1%)
and pancreatic cancer with 117 cases (1.1%).
22% of patients were included in study protocols. Focusing
on breast cancer: 96.5% of cases were ductal carcinoma,
99.5% treatments had curative intense and 113 cases were
re-treating with IORT.
Conclusion
Treatment chronology shows how IORT number of
recorded cases increased according with the interest in
this ISIORT project. This survey gives an overview of